Huntingdon Life Sciences and Harlan Laboratories Announce the Launch of the SHrNTM Novel Hairless NOD.SCID Model at AACR 2015

Huntingdon Life Sciences and Harlan Laboratories today announced the launch of the SHrN^TM – the world’s first hairless NOD.SCID mouse model to reach the market. SHrN^TM is triple-immunodeficient and is ideally suited for humanization and tumor xenografts. The model, which has applications in oncology and immunology-related research, was developed for use by academic, government, biopharmaceutical, and contract research scientists. SHrN^TM production will be managed in multiple Harlan facilities in the United States and Europe.

The SHrN^TM combines several highly desirable characteristics into one research model. It has both a functional deficit in NK cells and a deficiency in T and B cells. Preliminary phenotyping results for SHrN^TM have demonstrated promising benefits in cell uptake and tumor growth. Additionally, SHrN^TM has the advantage of a marked decrease in cell leakage compared to other SCID models. Genetic consistency is ensured through inbreeding which limits unwanted variability in research efforts. Lastly, as a hairless model, the SHrN^TM eliminates the need for shaving and enhances the observation of tumor growth and imaging clarity.

Dr. Adrian Hardy, Chief Operating Officer of the Huntingdon and Harlan organization, commented: “We are delighted to make available our innovative SHrN^TM hairless NOD.SCID mouse to the worldwide research community. The new model will help our customers in their important research that leads to bringing innovative therapies to patients.”

“The SHrN^TM was developed with the intent of improving both the effectiveness and convenience of the standard NOD.SCID model”, added Joe Meyer, Senior Vice President and General Manager of Harlan Laboratories, America’s: “At Huntingdon Life Sciences and Harlan Laboratories, we work closely with our customers to bring solutions to them that address gaps in the tools they use to support their research programs. As a consequence, we developed a NOD.SCID model that is hairless and slightly more immunocompromised to support the needs of scientists working in immunology, oncology, and other research areas.”

The company will introduce the SHrN^TM at the AACR (American Association for Cancer Research) Annual Meeting in Philadelphia from April 19-22 – Harlan booth (#719).